In general, the higher the BMI, the harder it is to take off weight and keep it off
Back in 2018, most of its earnings came from generics, with only a small share driven by innovation. Between 2025 and 2027, the company expects to bring dozens of major breakthroughs to market from GLP-1 therapies for obesity and diabetes to next-generation oncology treatments. Source: *Opinions are my own To view or add a comment, sign in Big Pharma News: Pfizer is set to acquire Metsera in a deal worth up to $4.9B Why it matters: $47.50/share upfront + $22.50/share tied to milestones Lead candidate MET-097i (GLP-1 therapy) showed 11.3% weight loss in 12 weeks Pipeline includes monthly amylin-based injections + oral obesity drugs Puts Pfizer head-to-head with Lilly & Novo Nordisk in the obesity race This move highlights the booming obesity drug market and pharmas growing appetite for metabolic innovation
This pudding works just as well half-eaten as it does fully finished, which makes it a solid small-meal option when appetite varies
They act as antioxidants, support gut bacteria, and some studies suggest they may enhance GLP-1 production and inhibit DPP-4 (an enzyme which breaks down GLP-1) [6]
I joined a Discord that I found from Reddit of peptide enthusiasts
Ibuprofen (200400 mg every 68 hours with food, maximum 1.2 g daily for over-the-counter use) may be used if paracetamol proves insufficient, provided you have no contraindications such as kidney disease, cardiovascular conditions, gastric ulcer history, or pregnancy (especially after 20 weeks)